Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Baxter
Merck
Moodys
Colorcon

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,790,675

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,790,675
Title:Method for increasing frataxin expression
Abstract: Use of human erythropoietin or a derivative of erythropoietin having the biological activity of human erythropoietin of increasing the expression of frataxin for the production of a pharmaceutical preparation for the treatment of Friedreich\'s ataxia or for the treatment or prevention of a disease associated with Friedreich\'s ataxia.
Inventor(s): Scheiber-Mojdehkar; Barbara (Vienna, AT), Sturm; Brigitte Nina (Vienna, AT)
Assignee: Medizinische Universitaet Wien (Vienna, AT)
Application Number:11/718,870
Patent Claims:1. A method of increasing frataxin expression in a subject having Friedreich's ataxia or a disease associated therewith, said subject being diagnosed as having decreased expression of frataxin, the method comprising: providing a pharmaceutical composition having a therapeutically effective amount of erythropoietin or a derivative thereof having the biological activity of human erythropoietin sufficient for increasing expression of frataxin, said human erythropoietin or said derivative thereof is selected from the group of recombinant human erythropoietin, erythropoietin .alpha., erythropoietin .beta., aranesp, asialoerythropoietin and carbamylated erythropoietin; and administering the pharmaceutical composition to the subject having Friedreich's ataxia or the disease associated therewith being a neurodegenerative disease, said administering increases frataxin expression in the subject.

2. A method according to claim 1, wherein the subject has Friedreich's ataxia diagnosed by means of gene analysis and/or ELISA and/or real-time PCR and that expression of frataxin is decreased due to GAA-repeat-expansion or mutations on one or on both alleles in the frataxin gene.

3. A method according to claim 1, wherein said disease associated with Friedreich's ataxia is a neurodegenerative disease, the subject having decreased expression of frataxin.

4. A method according to claim 1, wherein the subject is diagnosed by means of gene analysis and/or ELISA and/or real-time PCR and that expression of frataxin is decreased due to GAA-repeat-expansion or mutations on one or on both alleles in the frataxin gene.

5. A method of increasing expression of frataxin in a subject, said subject being diagnosed as having decreased expression of frataxin, the method comprising: providing a pharmaceutical composition having a therapeutically effective amount of an erythropoietin having the biological activity of human erythropoietin sufficient for increasing expression of frataxin, said erythropoietin is selected from the group of recombinant human erythropoietin, erythropoietin .alpha., erythropoietin .beta., aranesp, asialoerythropoietin and carbamylated erythropoietin; and administering the pharmaceutical composition to the subject so as to increase expression of frataxin in the subject.

6. A method as in claim 5, wherein the subject is diagnosed by means of gene analysis and/or ELISA and/or real-time PCR.

7. A method as in claim 5, wherein the expression of frataxin is decreased due to GAA-repeat-expansion or mutations on one or on both alleles in the frataxin gene.

8. A method as in claim 5, wherein the subject is diagnosed to have Friedreich's ataxia or a neurodegenerative disease associated with Friedreich's ataxia.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustriaA 1869/2004Nov 9, 2004
PCT Information
PCT FiledOctober 27, 2005PCT Application Number:PCT/EP2005/011510
PCT Publication Date:May 18, 2006PCT Publication Number:WO2006/050819

Details for Patent 7,790,675

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 001 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 002 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 003 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 004 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 005 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 006 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 007 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKinsey
Harvard Business School
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.